ResMedASX:RMD +3.29%98 Price-to-Owner-Earnings is 17.24 as of Jun. 24, 2026, which is 57% below its 10-year median of 40.09. GuruFocus rates ASX:RMD with a GF Score™ of 98/100 and a GF Value™ of A$38.56 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 310 Medical Devices & Instruments companies, ResMed ranks better than 68.06% on this metric.
As of today (2026-06-24), ResMed's share price is A$27.93.
ResMed's Owner Earnings per Share (TTM) ended in Mar. 2026 was A$1.62. It's Price-to-Owner-Earnings for today is 17.24.
The historical rank and industry rank for ResMed's Price-to-Owner-Earnings or its related term are showing as below:
ASX:RMD'
s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 16.48 Med: 40.09 Max: 198.69
Current: 16.71
During the past 13 years, the highest Price-to-Owner-Earnings of ResMed was 198.69. The lowest was 16.48. And the median was 40.09.
ASX:RMD's Price-to-Owner-Earnings is ranked better than 68.06% of 310
companies
in the Medical Devices & Instruments industry
Industry Median: 24.155
vs ASX:RMD: 16.71
As of today (2026-06-24), ResMed's share price is A$27.93.
ResMed's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was A$1.55. Therefore, ResMed's PE Ratio (TTM) for today is 18.04.
As of today (2026-06-24), ResMed's share price is A$27.93.
ResMed's EPS without NRI for the trailing twelve months (TTM) ended in was A$1.61. Therefore, ResMed's PE Ratio without NRI for today is 17.35.
During the past 13 years, ResMed's highestPE Ratio without NRI was 55.50. The lowest was 17.51. And the median was 30.20.
The historical data trend for ResMed's Price-to-Owner-Earnings can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RMD vs MDLN, WST, BDX: Price-to-Owner-Earnings Comparison
For the Medical Instruments & Supplies subindustry, ResMed's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ResMed Price-to-Owner-Earnings vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Price-to-Owner-Earnings distribution charts can be found below:
* The bar in red indicates where ResMed's Price-to-Owner-Earnings falls into.
"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."
ResMed's Price-to-Owner-Earnings for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Price-to-Owner-Earnings of 17.24 mean?
ResMed (ASX:RMD) has a Price-to-Owner-Earnings of 17.24 as of Jun. 24, 2026. Price-to-owner-earnings ratio is the ratio of share price to a company's Buffett owner earnings per share. View historical data on ResMed and its competitors. This is 57% below median its historical median of 40.09. Over the past decade, ResMed's Price-to-Owner-Earnings has ranged from 16.48 to 198.69. According to the industry distribution chart, ResMed ranks #99 out of 310 companies in the Medical Devices & Instruments industry, placing it in the top 31.9%.
Is ResMed's Price-to-Owner-Earnings too high?
ResMed's current Price-to-Owner-Earnings of 17.24 is 57% below median its 10-year median of 40.09. Over the past 10 years, this metric has ranged from a low of 16.48 to a high of 198.69. The Medical Devices & Instruments industry median Price-to-Owner-Earnings is 24.16. ResMed's value of 17.24 is 28.6% below this industry median. Based on the distribution chart, ResMed ranks #99 out of 310 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ResMed has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Price-to-Owner-Earnings compare to MDLN and WST?
According to the Medical Devices & Instruments industry distribution chart, ResMed ranks #99 out of 310 companies for Price-to-Owner-Earnings. This puts ResMed in the upper half of its industry. The industry median Price-to-Owner-Earnings is 24.16. ResMed's value of 17.24 is 28.6% below this benchmark. Historically, ResMed's own Price-to-Owner-Earnings has ranged from 16.48 to 198.69 over the past decade. While the company's 10-year median is 40.09 vs. the industry median of 24.16, ResMed has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Owner-Earnings for a Medical Devices & Instruments company?
The median Price-to-Owner-Earnings among Medical Devices & Instruments companies is 24.16, based on 310 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Owner-Earnings significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Owner-Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ResMed's current Price-to-Owner-Earnings of 17.24 is 28.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Owner-Earnings mean?
A high Price-to-Owner-Earnings can signal that a stock is expensive relative to its fundamentals. Price-to-owner-earnings ratio is the ratio of share price to a company's Buffett owner earnings per share. View historical data on ResMed and its competitors. For the Medical Devices & Instruments industry, the median Price-to-Owner-Earnings is 24.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ResMed's current Price-to-Owner-Earnings is 17.24, which is 57% below median its own 10-year median of 40.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (ASX:RMD) is currently considered Modestly Undervalued. The stock's GF Value™ is A$38.56, compared to a current price of A$27.93 — trading 27.6% below its estimated fair value. The current Price-to-Owner-Earnings is 17.24, which is 57% below median its 10-year median of 40.09 and 28.6% below the Medical Devices & Instruments industry median of 24.16. ResMed's overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Owner-Earnings calculated?
Price-to-Owner-Earnings is calculated from a company's financial statements. For ResMed (ASX:RMD), the current Price-to-Owner-Earnings is 17.24 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ResMed (ASX:RMD) Overvalued in 2026?
Based on GuruFocus' analysis, ResMed stock appears to be undervalued.
The current stock price of A$27.93 is trading 27.6% below its estimated GF Value™ of A$38.56.
GuruFocus considers ResMed to be Modestly Undervalued.
Key valuation signals for ASX:RMD:
Price-to-Owner-Earnings: 17.24 (57% below median its 10-year median of 40.09)
GF Value™: A$38.56 vs. price of A$27.93 (27.6% below fair value)
Industry Position: 28.6% below the Medical Devices & Instruments median (#99 of 310)
No single metric tells the full story. See the ASX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
98GF Score
Get the complete analysis for ASX:RMD
Price-to-Owner-Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RMD has been successfully added to your 
